395 related articles for article (PubMed ID: 36587890)
1. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
3. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
[TBL] [Abstract][Full Text] [Related]
4. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
7. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
[TBL] [Abstract][Full Text] [Related]
10. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
[TBL] [Abstract][Full Text] [Related]
11. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S
Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
[TBL] [Abstract][Full Text] [Related]
12. Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D).
Gang S; Khetan P; Varade D; Chinta VR; Mavani S; Gupta U; Reddy SVK; Rajanna S; Jeloka T; Ruhela V; Kansagra K; Kanani P; Bhatt J; Zala K;
Am J Nephrol; 2022; 53(5):343-351. PubMed ID: 35462369
[TBL] [Abstract][Full Text] [Related]
13. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin for the anaemia of chronic kidney disease.
Palmer SC; Saglimbene V; Craig JC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009297. PubMed ID: 24683046
[TBL] [Abstract][Full Text] [Related]
15. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
Macdougall IC; Walker R; Provenzano R; de Alvaro F; Locay HR; Nader PC; Locatelli F; Dougherty FC; Beyer U;
Clin J Am Soc Nephrol; 2008 Mar; 3(2):337-47. PubMed ID: 18287255
[TBL] [Abstract][Full Text] [Related]
16. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
17. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Alsalimy N; Awaisu A
Int J Clin Pharm; 2014 Dec; 36(6):1115-25. PubMed ID: 25288147
[TBL] [Abstract][Full Text] [Related]
18. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
19. Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.
Locatelli F; Choukroun G; Truman M; Wiggenhauser A; Fliser D
Adv Ther; 2016 Apr; 33(4):610-25. PubMed ID: 26965694
[TBL] [Abstract][Full Text] [Related]
20. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]